首页> 外文期刊>Urology >Inhibitory effects of T/L-type calcium channel blockers on tubulointerstitial fibrosis in obstructed kidneys in rats.
【24h】

Inhibitory effects of T/L-type calcium channel blockers on tubulointerstitial fibrosis in obstructed kidneys in rats.

机译:T / L型钙通道阻滞剂对大鼠肾脏阻塞性肾小管间质纤维化的抑制作用。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To examine the effect of L- and T/L-type calcium channel blockers on interstitial fibrosis in chronic unilateral ureteral obstruction (UUO). Tubulointerstitial fibrosis is a common outcome of several progressive renal diseases. Calcium channel blockers are widely used for the treatment of hypertension with renal diseases; however, the direct effect of calcium channel blockers on renal diseases independent of lowering blood pressure has not been fully elucidated. METHODS: Sprague-Dawley rats were divided into 3 treatment groups: (1) vehicle control; (2) nifedipine, an L-type calcium channel blockers; and (3) efonidipine, a T/L-type calcium channel blockers. Treatment was initiated 1 day before and continued until 6 days after creation of the UUO. RESULTS: Tubulointerstitial fibrosis in the obstructed kidney was significantly increased compared with that in the contralateral unobstructed kidney. Furthermore, the increased fibrosis was accompanied by increased fibrogenic signaling expressed by transforming growth factor beta1 and connective tissue growth factor mRNA levels, increased oxidative stress expressed by p22phox, p47phox and gp91phox mRNA level. Moreover, treatment with a nonhypotensive dose of efonidipine but not nifedipine in the obstructed kidney significantly suppressed the fibrogenic signaling and the oxidative stress, resulting in reduced tubulointerstitial fibrosis. The plasma aldosterone level in efonidipine-treated animals was increased compared with vehicle-treated animals, although not significantly. The increased plasma aldosterone level did not increase sgk-1 mRNA level in efonidipine but not in nifedipine treated animals. CONCLUSIONS: Treatment with efonidipine improved tubulointerstitial fibrosis more effectively than treatment with nifedipine in UUO. The antifibrogenic effect by efonidipine was obtained through suppression of fibrogenic signaling.
机译:目的:研究L型和T / L型钙通道阻滞剂对慢性单侧输尿管梗阻(UUO)间质纤维化的影响。肾小管间质纤维化是几种进行性肾脏疾病的常见结局。钙通道阻滞剂被广泛用于治疗高血压和肾脏疾病。然而,尚未完全阐明钙通道阻滞剂对肾脏疾病的独立影响,而与降低血压无关。方法:将Sprague-Dawley大鼠分为3个治疗组:(1)媒介物对照组; (2)硝苯地平,一种L型钙通道阻滞剂; (3)依非地平,一种T / L型钙通道阻滞剂。在UUO产生前1天开始治疗,并持续到6天后。结果:与对侧无阻塞肾脏相比,阻塞性肾脏中的肾小管间质纤维化明显增加。此外,纤维化增加伴随着由转化生长因子β1和结缔组织生长因子mRNA水平表达的纤维化信号的增加,由p22phox,p47phox和gp91phox mRNA水平表达的氧化应激的增加。此外,在阻塞性肾脏中用非降压剂量的依非替尼而不是硝苯地平进行治疗可显着抑制纤维化信号和氧化应激,从而降低肾小管间质纤维化。依非地平治疗的动物的血浆醛固酮水平与溶媒治疗的动物相比有所升高,尽管并不显着。在依非地平中,血浆醛固酮水平的升高并未使sgk-1 mRNA水平升高,但在硝苯地平治疗的动物中并未升高。结论:在非UOO中,依非替尼治疗比硝苯地平治疗更有效地改善了肾小管间质纤维化。依非地平的抗纤维化作用是通过抑制纤维化信号传导而获得的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号